• Strong start on underlying revenue and profitability led by Growth Drivers and Opex discipline
• Reported operating profit and EPS impacted by large transactions in Q1 FY2017: 106.3 billion yen one-time gain on the sale of Wako and 16.8 billion yen from the 2nd tranche of products sold to Teva JV. Operating profit excluding these items was +37.5%
Print
OSAKA, Japan-Thursday 2 August 2018 [ AETOS Wire ]
(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502):
Underlying Revenue growth +6.4% with growth in every region
Underlying Revenue grew +6.4%, led by Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) displaying strong growth of +11.8% over prior year. Key products Entyvio (+34.1%) and Ninlaro (+43.3%) made important contributions to revenue growth.
Underlying Revenue increased in every region, particularly the U.S. whic
...
Read more »